24AA Preclinical
MGF
A 24-amino-acid IGF-1Ec E-peptide splice variant released within minutes of muscle damage, activating satellite cells through a receptor pathway distinct from IGF-1 — with a ~5–7 min serum half-life that keeps its action tightly local and transient.
In Plain English:
Every time you tear a muscle fibre — whether from lifting or injury — your body produces two signals from the same IGF-1 gene. One is standard IGF-1 (long-range rebuilding). The other is MGF, a short 24-amino-acid peptide cut from the tail end of the IGF-1Ec splice variant. MGF is the immediate-response signal: it appears within hours, wakes up dormant satellite stem cells sitting alongside the muscle fibre, tells them to multiply and not yet fuse into mature muscle, then vanishes in roughly five minutes because blood enzymes shred it. That brief burst prevents premature differentiation so there are enough stem cells to properly repair the damage. Researchers study synthetic MGF because it appears to work through a pathway separate from the main IGF-1 receptor, raising hopes for targeted muscle repair, neuroprotection after stroke, and cardiac protection after heart attack — all without the full hormonal load of IGF-1. PEGylated MGF (PEG-MGF) extends the half-life to 24–72 hours, making it more practical to study. No human clinical trials have been completed; all therapeutic evidence is preclinical.
Research Maturity
Preclinical (~150+ PubMed-indexed publications on MGF / IGF-1Ec; entirely preclinical+ Studies)
Focus
Muscle Repair
Performance & Recovery
Origin
MGF is the C-terminal E-peptide derived from the IGF-1Ec mRNA splice variant, first characterised in mechanically loaded rabbit tibialis anterior muscle by Goldspink et al. in 1996 (J Physiol 495:469–73). The 24-amino-acid synthetic E-peptide corresponds to residues encoded by the Ec exon insert unique to the IGF-1Ec isoform. It is expressed endogenously in skeletal muscle, heart, brain, bone, and prostate in response to mechanical load or tissue damage. The synthetic form is produced by solid-phase peptide synthesis; a PEGylated variant (PEG-MGF) attaches polyethylene glycol to extend circulatory half-life. No regulatory approval exists in any jurisdiction for human therapeutic use.
Mechanism
MGF E-peptide signals through a mechanism distinct from the IGF-1 receptor (IGF-1R): anti-IGF-1R antibodies do not fully abolish its mitogenic effects, and Gd3+ (a non-selective cation channel blocker) partially inhibits it, suggesting involvement of a putative MGF-specific receptor or co-receptor. Downstream, the peptide activates p38 MAPK and suppresses caspase-3, producing anti-apoptotic protection. In satellite cells it drives proliferation without premature myogenic differentiation — consistent with a 'phase 1' role (0–24 h post-injury) before IGF-1Ea takes over differentiation in phase 2. Nuclear localisation signals within the E-peptide sequence suggest possible intracrine transcriptional effects independent of surface receptor binding. PKC and Nrf2 pathways have also been implicated. Cardioprotective effects in myocardial infarction models appear superior to mature IGF-1, mediated at least partly through ERK1/2 and PI3K/Akt without engaging the full IGF-1R cascade at therapeutic doses.
Outcome
Preclinical endpoints studied: satellite cell proliferation rate, myofibre cross-sectional area, muscle regeneration speed after injury (bupivacaine or freeze-crush models), ACL fibroblast migration via Rac1-PAK1/2 and RhoA-ROCK1 pathways, cardiac function after myocardial infarction, neuronal survival after hypoxia-ischaemia and traumatic brain injury, osteoblast proliferation and bone defect healing, neural progenitor cell count in dentate gyrus and subventricular zone, and cartilage chondrocyte behaviour in silk-scaffold articular regeneration models.
